TAKEDA PHARMA (TKD HM) stock market data APIs
€24.3168
0.11(0.5%)
as of December 17, 2025
Try our APIs with
free plan!
TAKEDA PHARMA Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for TKD.HM.
Prev. Close
24.3168
Open
24.4285
High
24.7617
Low
24.2849
52 wk Range
23.11-27.1187
Market Cap
37 823 M
Dividends (Yield)
3.2068
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get TAKEDA PHARMA data using free add-ons & libraries
Get TAKEDA PHARMA Fundamental Data
TAKEDA PHARMA Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
TAKEDA PHARMA News
New
Takeda Pharmaceutical's Potential Plaque Psoriasis Therapy Meets Endpoints in Phase 3 Studies
Takeda Pharmaceutical (TAK) said Thursday its drug zasocitinib for the treatment of adults with mode PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment
Pivotal Phase 3 studies of once-daily oral zasocitinib met all primary and ranked secondary endpoints in patients with moderate-to-severe plaque psoriasis More than half of study participants treated ...
BaseLaunch Announces the Addition of Takeda as New Pharmaceutical Partner to its Biotech Venture Incubator
Takeda will join five existing leading pharma company partners supporting and funding promising drug development startups. BASEL, Switzerland, Dec. 16, 2025 /PRNewswire/ -- BaseLaunch, a platform to ...
British Columbia reimburses FRUZAQLATM (fruquintinib capsules) for the treatment of metastatic colorectal cancer (mCRC)
TORONTO, Dec. 16, 2025 /CNW/ - Takeda Canada Inc. ("Takeda") is pleased to announce that FRUZAQLATM (fruquintinib capsules) will now be reimbursed by BC Cancer as a treatment option for adult patients...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
